IL148997A0 - Bicyclic imidazo-3-yl-amine derivatives - Google Patents

Bicyclic imidazo-3-yl-amine derivatives

Info

Publication number
IL148997A0
IL148997A0 IL14899700A IL14899700A IL148997A0 IL 148997 A0 IL148997 A0 IL 148997A0 IL 14899700 A IL14899700 A IL 14899700A IL 14899700 A IL14899700 A IL 14899700A IL 148997 A0 IL148997 A0 IL 148997A0
Authority
IL
Israel
Prior art keywords
amine derivatives
bicyclic imidazo
imidazo
bicyclic
amine
Prior art date
Application number
IL14899700A
Other languages
English (en)
Original Assignee
Gruenenthal Chemie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruenenthal Chemie filed Critical Gruenenthal Chemie
Priority claimed from PCT/EP2000/009096 external-priority patent/WO2001027111A2/de
Publication of IL148997A0 publication Critical patent/IL148997A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/06—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
IL14899700A 1999-10-08 2000-09-18 Bicyclic imidazo-3-yl-amine derivatives IL148997A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19948434A DE19948434A1 (de) 1999-10-08 1999-10-08 Substanzbibliothek enthaltend bicyclische Imidazo-5-amine und/oder bicyclische Imidazo-3-amine
PCT/EP2000/009096 WO2001027111A2 (de) 1999-10-08 2000-09-18 Bicyclische imidazo-3-yl-aminderivate

Publications (1)

Publication Number Publication Date
IL148997A0 true IL148997A0 (en) 2002-11-10

Family

ID=7924888

Family Applications (3)

Application Number Title Priority Date Filing Date
IL14899700A IL148997A0 (en) 1999-10-08 2000-09-18 Bicyclic imidazo-3-yl-amine derivatives
IL14899900A IL148999A0 (en) 1999-10-08 2000-10-06 Tert-butyl-(7-methyl-imidazo [1, 2-a] pyridine-3-yl)-amine derivatives
IL148999A IL148999A (en) 1999-10-08 2002-04-04 Pharmaceutical preparations containing a history of tart butyl - (7 - methyl – imidazo [a – 1,2] pyridine - 3 - ile) - reliable, several such histories and their preparation

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL14899900A IL148999A0 (en) 1999-10-08 2000-10-06 Tert-butyl-(7-methyl-imidazo [1, 2-a] pyridine-3-yl)-amine derivatives
IL148999A IL148999A (en) 1999-10-08 2002-04-04 Pharmaceutical preparations containing a history of tart butyl - (7 - methyl – imidazo [a – 1,2] pyridine - 3 - ile) - reliable, several such histories and their preparation

Country Status (28)

Country Link
US (1) US6703404B2 (enExample)
EP (1) EP1218378B1 (enExample)
JP (1) JP2003511450A (enExample)
KR (1) KR100793619B1 (enExample)
CN (1) CN1208336C (enExample)
AR (2) AR025959A1 (enExample)
AT (1) ATE238304T1 (enExample)
AU (2) AU7419900A (enExample)
BR (1) BR0014827A (enExample)
CA (1) CA2386804A1 (enExample)
CO (2) CO5210861A1 (enExample)
CZ (1) CZ20021241A3 (enExample)
DE (2) DE19948434A1 (enExample)
DK (1) DK1218378T3 (enExample)
ES (1) ES2198355T3 (enExample)
HK (1) HK1047749B (enExample)
HU (1) HUP0203545A3 (enExample)
IL (3) IL148997A0 (enExample)
MX (1) MXPA02003546A (enExample)
NO (1) NO20021564L (enExample)
NZ (1) NZ518438A (enExample)
PE (2) PE20010632A1 (enExample)
PL (1) PL355109A1 (enExample)
PT (1) PT1218378E (enExample)
RU (1) RU2002110281A (enExample)
SK (1) SK4622002A3 (enExample)
WO (2) WO2001027119A2 (enExample)
ZA (2) ZA200203579B (enExample)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6083966A (en) 1998-08-31 2000-07-04 University Of Florida Thiazoline acid derivatives
CN1585639A (zh) 1998-09-21 2005-02-23 佛罗里达大学研究基金会 抗疟疾制剂
US6380228B1 (en) 2000-04-10 2002-04-30 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
DE10043845A1 (de) * 2000-09-06 2002-03-14 Gruenenthal Gmbh Verfahren zur Messung der Aktivität der NO-Synthase
DE10050663A1 (de) * 2000-10-13 2002-04-18 Gruenenthal Gmbh Verwendung von substituierten Imidazo[1,2-a]pyridin-, -pyrimidin- und pyrazin-3-yl-amin-Derivaten zur Herstellung von Medikamenten zur NOS-Inhibierung
EP1343785A2 (de) * 2000-12-13 2003-09-17 Basf Aktiengesellschaft Verwendung von substituierten imidazoazinen, neue imidazoazine, verfahren zu deren herstellung, sowie sie enthaltende mittel
DE10117184A1 (de) * 2001-04-05 2002-10-17 Gruenenthal Gmbh Substituierte Imidazol[1,2-a]-pyridin-3-yl-amid- und -aminverbindungen
DE10117183A1 (de) * 2001-04-05 2002-10-10 Gruenenthal Gmbh Verwendung von substituierten Imidazo[1,2-a]-pyridinverbindungen als Arzneimittel
DE10132726A1 (de) 2001-07-05 2003-02-27 Gruenenthal Gmbh Verwendung von substituierten gamma-Lactonverbindungen als Arzneimittel
AU2003223049A1 (en) 2002-03-13 2003-09-22 Euro-Celtique S.A. Aryl substituted pyrimidines and the use thereof
IL164703A0 (en) 2002-04-19 2005-12-18 Cellular Genomics Inc ImidazoÄ1,2-AÜpyrazin-8-ylamines method of making and method of use thereof
US20050197435A1 (en) * 2002-06-14 2005-09-08 Dotson Darin L. Polymer additive compositions for bimolecular nucleation in thermoplastics
AU2003270489A1 (en) 2002-09-09 2004-03-29 Cellular Genomics, Inc. 6-ARYL-IMIDAZO(1,2-a)PYRAZIN-8-YLAMINES, METHOD OF MAKING, AND METHOD OF USE THEREOF
DE10246890A1 (de) 2002-10-08 2004-04-22 Grünenthal GmbH Substituierte C-Imidazo[1,2-alpyridin-3-yl-methylamine
WO2004058755A2 (en) * 2002-12-24 2004-07-15 Biofocus Plc Compound libraries of imidazo[1,5-a]pyridin-3-yl derivatives and related heterobicycles for targetting compounds capable of binding to g-protein coupled receptors
WO2004072080A1 (en) 2003-02-10 2004-08-26 Cellular Genomics, Inc. Certain 8-heteroaryl-6-phenyl-imidazo[1,2-a]pyrazines as modulators of hsp90 complex activity
US7405295B2 (en) 2003-06-04 2008-07-29 Cgi Pharmaceuticals, Inc. Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds
WO2005005429A1 (en) 2003-06-30 2005-01-20 Cellular Genomics, Inc. Certain heterocyclic substituted imidazo[1,2-a]pyrazin-8-ylamines and methods of inhibition of bruton’s tyrosine kinase by such compounds
WO2005019220A2 (en) 2003-08-11 2005-03-03 Cellular Genomics Inc. Substituted imidazo[1,2-a]pyrazines as modulators of kinase activity
WO2005034949A1 (en) 2003-09-09 2005-04-21 University Of Florida Desferrithiocin derivatives and their use as iron chelators
DE102004021716A1 (de) * 2004-04-30 2005-12-01 Grünenthal GmbH Substituierte Imidazo[1,2-a]pyridin-Verbindungen und Arzneimittel enthaltend substituierte Imidazo[1,2-a]pyridin-Verbindungen
DE102004044884A1 (de) * 2004-09-14 2006-05-24 Grünenthal GmbH Substituierte bizyklische Imidazo-3-yl-amin-Verbindungen
US7622486B2 (en) 2004-09-23 2009-11-24 Reddy Us Therapeutics, Inc. Pyridine compounds, process for their preparation and compositions containing them
DK1866296T3 (en) 2005-04-04 2017-02-13 Univ Florida DESFERRITHIOCINPOLYETHER-ANALOGS
DE102005016547A1 (de) * 2005-04-08 2006-10-12 Grünenthal GmbH Substituierte 5,6,7,8-Tetrahydro-imidazo(1,2-a)pyridin-2-ylamin-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln
US7777040B2 (en) 2005-05-03 2010-08-17 Cgi Pharmaceuticals, Inc. Certain substituted ureas, as modulators of kinase activity
KR20080038278A (ko) 2005-05-20 2008-05-06 어레이 바이오파마 인크. Ｒａｆ 억제제 화합물 및 그의 사용 방법
US7855289B2 (en) 2005-08-04 2010-12-21 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
US8088928B2 (en) 2005-08-04 2012-01-03 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
EP2388263A1 (en) 2005-08-04 2011-11-23 Sirtris Pharmaceuticals, Inc. Imidazo[2,1-b]thiazole derivatives as sirtuin modulators
US8093401B2 (en) 2005-08-04 2012-01-10 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
JP2009507032A (ja) 2005-09-02 2009-02-19 アボット・ラボラトリーズ 新規なイミダゾ系複素環
ES2761180T3 (es) 2005-12-23 2020-05-19 Ariad Pharma Inc Compuestos bicíclicos de heteroarilo
DE102006011574A1 (de) 2006-03-10 2007-10-31 Grünenthal GmbH Substituierte Imidazo[2,1-b]thiazol-Verbindungen und ihre Verwendung zur Herstellung von Arzneimitteln
TWI409267B (zh) 2006-03-17 2013-09-21 Ambit Biosciences Corp 治療疾病用之咪唑并噻唑化合物
BRPI0809077A2 (pt) 2007-03-15 2014-09-09 Univ Florida Res Foudantion Inc Análogos de poliéter de desferritiocina
WO2008134553A1 (en) * 2007-04-26 2008-11-06 Xenon Pharmaceuticals Inc. Methods of using bicyclic compounds in treating sodium channel-mediated diseases
GB0708188D0 (en) * 2007-04-27 2007-06-06 Merck Sharp & Dohme Therapeutic compounds
TW200916472A (en) 2007-06-20 2009-04-16 Sirtris Pharmaceuticals Inc Sirtuin modulating compounds
CL2008001821A1 (es) 2007-06-20 2009-03-13 Sirtris Pharmaceuticals Inc Compuestos derivados de imidazo[2,1-b]-tiazol; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de diabetes, sindrome metabolico, resistencia a la insulina, entre otras.
DE102007040336A1 (de) * 2007-08-27 2009-03-05 Johann Wolfgang Goethe-Universität Frankfurt am Main Neue Inhibitoren der 5-Lipoxygenase und deren Verwendungen
KR20150104231A (ko) 2007-09-19 2015-09-14 암비트 바이오사이언시즈 코포레이션 Ｎ-(5-ｔｅｒｔ-부틸-이속사졸-3-일)-Ｎ''-[4-[7-(2-모르폴린-4-일-에톡시)이미다조[2,1-Ｂ][1,3]벤조티아졸-2-일]페닐]우레아를 포함하는 고체 형태, 그의 조성물 및 그의 용도
NZ587039A (en) 2008-02-13 2013-01-25 Gilead Connecticut Inc 6-aryl-imidazo[1, 2-a]pyrazine derivatives, method of making, and method of use thereof
BRPI0911659B8 (pt) * 2008-04-15 2021-05-25 Eisai R&D Man Co Ltd composto 3-fenilpirazolo[5,1-b]tiazol e composição farmacêutica compreendendo o mesmo
WO2010032195A1 (en) * 2008-09-16 2010-03-25 Csir Imidazopyridines and imidazopyrimidines as hiv-i reverse transcriptase inhibitors
US8450321B2 (en) 2008-12-08 2013-05-28 Gilead Connecticut, Inc. 6-(1H-indazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo-[1,2-A]pyrazin-8-amine, or a pharmaceutically acceptable salt thereof, as a SYK inhibitor
SG171993A1 (en) 2008-12-08 2011-07-28 Gilead Connecticut Inc Imidazopyrazine syk inhibitors
CN104744476B (zh) 2008-12-08 2017-04-12 吉利德康涅狄格公司 咪唑并吡嗪syk抑制剂
CA2747715A1 (en) 2008-12-19 2010-06-24 Sirtris Pharmaceuticals, Inc. Thiazolopyridine sirtuin modulating compounds
AR078521A1 (es) * 2009-10-08 2011-11-16 Eisai R&D Man Co Ltd Compuesto pirazolotiazol
NZ602362A (en) 2010-03-11 2014-11-28 Gilead Connecticut Inc Imidazopyridines syk inhibitors
JP6539046B2 (ja) 2011-12-16 2019-07-03 ユニバーシティー オブ フロリダ リサーチ ファンデーション， インク． ４’−デスフェリチオシン類似体の使用
BR112014026493A2 (pt) 2012-04-26 2017-06-27 Bristol Myers Squibb Co derivados de imidazotiadiazol como inibidores do receptor ativado por protease 4 (par4) para tratar a agregação de plaqueta
JP6073464B2 (ja) 2012-04-26 2017-02-01 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 血小板凝集を治療するためのプロテアーゼ活性化受容体４（ｐａｒ４）阻害剤としてのイミダゾチアジアゾールおよびイミダゾピラジン誘導体
WO2013163241A1 (en) 2012-04-26 2013-10-31 Bristol-Myers Squibb Company Imidazothiadiazole and imidazopyridazine derivatives as protease activated receptor 4 (par4) inhibitors for treating platelet aggregation
KR20150082308A (ko) * 2012-11-14 2015-07-15 에프. 호프만-라 로슈 아게 이미다조피리딘 유도체
EA201791873A1 (ru) 2013-07-30 2018-09-28 Джилид Коннектикут, Инк. Полиморф ингибиторов syk
EP3027171B1 (en) 2013-07-30 2020-03-25 Gilead Connecticut, Inc. Formulation of syk inhibitors
EP3071201A4 (en) 2013-11-22 2017-04-26 University of Florida Research Foundation, Inc. Desferrithiocin analogs and uses thereof
KR20180002888A (ko) 2013-12-04 2018-01-08 길리애드 사이언시즈, 인코포레이티드 암을 치료하는 방법
US9290505B2 (en) 2013-12-23 2016-03-22 Gilead Sciences, Inc. Substituted imidazo[1,2-a]pyrazines as Syk inhibitors
UY35898A (es) 2013-12-23 2015-07-31 Gilead Sciences Inc ?compuestos inhibidores de syk y composiciones que los comprenden?.
US9493442B2 (en) 2014-02-13 2016-11-15 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
TWI720451B (zh) 2014-02-13 2021-03-01 美商英塞特控股公司 作為lsd1抑制劑之環丙胺
US9527835B2 (en) 2014-02-13 2016-12-27 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
KR102421235B1 (ko) 2014-02-13 2022-07-15 인사이트 코포레이션 Lsd1 저해제로서 사이클로프로필아민
US9617279B1 (en) 2014-06-24 2017-04-11 Bristol-Myers Squibb Company Imidazooxadiazole compounds
US9598419B1 (en) 2014-06-24 2017-03-21 Universite De Montreal Imidazotriazine and imidazodiazine compounds
WO2016007722A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
US9758523B2 (en) 2014-07-10 2017-09-12 Incyte Corporation Triazolopyridines and triazolopyrazines as LSD1 inhibitors
TW201613925A (en) 2014-07-10 2016-04-16 Incyte Corp Imidazopyrazines as LSD1 inhibitors
TWI687419B (zh) 2014-07-10 2020-03-11 美商英塞特公司 作為ｌｓｄ１抑制劑之咪唑并吡啶及咪唑并吡嗪
CN106687139A (zh) 2014-07-14 2017-05-17 吉利德科学公司 用于治疗癌症的组合
SG11201708047UA (en) 2015-04-03 2017-10-30 Incyte Corp Heterocyclic compounds as lsd1 inhibitors
CN107708693A (zh) 2015-04-27 2018-02-16 佛罗里达大学研究基金会 代谢程序化的金属螯合剂及其用途
CN110402244B (zh) 2015-08-12 2023-02-03 因赛特公司 Lsd1抑制剂的盐
SG10202010414QA (en) 2016-04-22 2020-11-27 Incyte Corp Formulations of an lsd1 inhibitor
WO2019014514A1 (en) * 2017-07-14 2019-01-17 University Of Massachusetts HETEROCYCLIC COMPOUNDS AND USES THEREOF
CN111051311A (zh) 2017-08-25 2020-04-21 吉利德科学公司 Syk抑制剂的多晶型物
US11530209B2 (en) * 2017-10-04 2022-12-20 Dana-Farber Cancer Institute, Inc. Small molecule inhibition of transcription factor SALL4 and uses thereof
WO2020047198A1 (en) 2018-08-31 2020-03-05 Incyte Corporation Salts of an lsd1 inhibitor and processes for preparing the same
KR20210131372A (ko) 2019-02-22 2021-11-02 크로노스 바이오, 인코포레이티드 Syk 억제제로서의 축합된 피라진의 고체 형태
WO2024220541A1 (en) * 2023-04-18 2024-10-24 Kallyope, Inc. Nk3 modulators and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3489755A (en) 1966-08-03 1970-01-13 Pfizer & Co C Imidazo (1,2-b) pyridazines
FR2463774A1 (fr) * 1979-08-21 1981-02-27 Yamanouchi Pharma Co Ltd Derives du 2-phenylimidazo(2,1-b)benzothiazole
DE3269604D1 (en) * 1981-06-26 1986-04-10 Schering Corp Novel imidazo(1,2-a)pyridines and pyrazines, processes for their preparation and pharmaceutical compositions containing them
NZ221996A (en) * 1986-10-07 1989-08-29 Yamanouchi Pharma Co Ltd Imidazo-pyridine derivatives and pharmaceutical compositions
FR2638161B1 (fr) * 1988-10-24 1991-01-11 Centre Nat Rech Scient Nouvelles benzoyl-2 imidazo (1,2-a) pyridines et leurs sels, leur procede de preparation, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant
JPH08333258A (ja) * 1994-12-14 1996-12-17 Japan Tobacco Inc チアジン又はチアゼピン誘導体及びそれら化合物を含有してなる一酸化窒素合成酵素阻害剤
GB9506188D0 (en) * 1995-03-27 1995-05-17 Fujisawa Pharmaceutical Co Amidine derivatives
US5908842A (en) * 1995-12-08 1999-06-01 Merck & Co., Inc. Substituted 2-acylamino-pyridines as inhibitors of nitric oxide synthase
WO1998006724A1 (en) * 1996-08-09 1998-02-19 Yamanouchi Pharmaceutical Co., Ltd. Metabotropic glutamate receptor agonists
AUPP278498A0 (en) * 1998-04-03 1998-04-30 Australian Nuclear Science & Technology Organisation Peripheral benzodiazepine receptor binding agents

Also Published As

Publication number Publication date
PL355109A1 (en) 2004-04-05
AU780526B2 (en) 2005-03-24
DE19948434A1 (de) 2001-06-07
NO20021564L (no) 2002-06-04
CO5210861A1 (es) 2002-10-30
HUP0203545A3 (en) 2004-07-28
SK4622002A3 (en) 2002-09-10
US6703404B2 (en) 2004-03-09
HK1047749A1 (en) 2003-03-07
ZA200203581B (en) 2004-02-25
IL148999A (en) 2007-03-08
CZ20021241A3 (cs) 2002-08-14
KR100793619B1 (ko) 2008-01-11
EP1218378B1 (de) 2003-04-23
WO2001027119A3 (de) 2001-10-11
JP2003511450A (ja) 2003-03-25
WO2001027109A3 (de) 2001-09-20
CO5251429A1 (es) 2003-02-28
EP1218378A2 (de) 2002-07-03
RU2002110281A (ru) 2003-12-20
AU7419900A (en) 2001-04-23
ES2198355T3 (es) 2004-02-01
ATE238304T1 (de) 2003-05-15
HK1047749B (zh) 2003-08-22
MXPA02003546A (es) 2002-09-18
AR025959A1 (es) 2002-12-26
AU7915300A (en) 2001-04-23
US20030022914A1 (en) 2003-01-30
DE50001911D1 (de) 2003-05-28
HUP0203545A2 (hu) 2003-02-28
CN1208336C (zh) 2005-06-29
AR025960A1 (es) 2002-12-26
BR0014827A (pt) 2003-07-08
WO2001027119A2 (de) 2001-04-19
NO20021564D0 (no) 2002-04-03
CN1407983A (zh) 2003-04-02
WO2001027109A2 (de) 2001-04-19
NZ518438A (en) 2004-08-27
PT1218378E (pt) 2003-09-30
IL148999A0 (en) 2002-11-10
PE20010706A1 (es) 2001-08-13
KR20020069003A (ko) 2002-08-28
ZA200203579B (en) 2003-10-29
PE20010632A1 (es) 2001-07-07
CA2386804A1 (en) 2001-04-19
DK1218378T3 (da) 2003-07-21

Similar Documents

Publication Publication Date Title
IL148997A0 (en) Bicyclic imidazo-3-yl-amine derivatives
PL355206A1 (en) Bicyclic imidazo-3-yl-amine derivatives
EG23817A (en) 4-Phenyl-pyridine derivatives
IL148167A0 (en) Amino-triazolopyridine derivatives
GC0000183A (en) 3-Phenyl-pyridine derivatives
IL149010A0 (en) Bicyclic imidazo-5-yl-amine derivatives
GC0000338A (en) 5-Phenyl-pyrimidine derivatives
IL145739A0 (en) 13-methyl-erythromycin derivatives
PL353876A1 (en) Substituted 2-dialkylaminoalkylbiphenyl derivatives
IL148837A0 (en) Isoxazolecarboxamide derivatives
GC0000191A (en) 4-Phenyl-pyrimidine derivatives
GC0000256A (en) Ethanesulfonyl-piperidine derivatives
GB9925880D0 (en) B-Carboline derivatives
IL150132A0 (en) Cyclopenteneone derivatives
IL147636A0 (en) 3-amino-2-benzyl-1-phenyl-propane derivatives
IL145949A0 (en) 1-trifluoromethyl-4-hydroxy-7-piperidinyl-aminomethylchroman derivatives
PL351407A1 (en) Thio-oxindole derivatives
GB0027548D0 (en) Bicyclic amide derivatives
SI1218382T1 (en) Bicyclic imidazo-3-yl-amine derivatives
ZA200203582B (en) Bicyclic imidazo-5-yl-amine derivatives.
IL146282A0 (en) Thio-oxindole derivatives
GB9907134D0 (en) Antimor napthylcombretastatin derivatives
SI1178984T1 (en) 1-trifluoromethyl-4-hydroxy-7-piperidinyl-aminomethylchroman derivatives
SI1200445T1 (en) Thienopyranecarboxamide derivatives
SI1226131T1 (en) Isoxazolecarboxamide derivatives

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees